Table 5. Univariate and multivariate hazards ratios for overall survival in 248 patients with metastatic non-small cell lung cancer.
Univariate | Multivariate | |||||
Variables | HR | 95% CI | P | HR | 95% CI | P |
Histology | ||||||
Adeno | 1 | 1 | ||||
Squamous | 1.2 | 0.7–2.1 | 0.41 | 1.2 | 0.7–2.1 | 0.48 |
Large Cell | 1.8 | 1.2–2.8 | <0.01 | 2.2 | 1.4–3.4 | <0.01 |
Mutation result | ||||||
EGFR/ KRAS WT | 1 | 1 | ||||
EGFR mutation | 0.4 | 0.2–0.7 | <0.01 | 0.3 | 0.1–0.6 | <0.01 |
KRAS mutation | 1.1 | 0.7–1.5 | 0.70 | 1.1 | 0.8–1.8 | 0.34 |
No test performed | 1.2 | 0.8–1.9 | 0.33 | 1.4 | 0.8–2.1 | 0.31 |
Metastasis * | ||||||
Spinal bone | 1.5 | 1.0–2.2 | 0.05 | 1.7 | 1.2–2.6 | <0.01 |
Brain | 0.9 | 0.6–1.4 | 0.67 | |||
Lung | 1.1 | 0.8–1.5 | 0.64 |
HR>1 means a shorter survival.
denotes presence of metastasis at specific site.